Bottom line
JDOC vs HRTS: the short answer
JDOC (JPMorgan Healthcare Leaders ETF) and HRTS (Tema Heart & Health ETF) share a meaningful slice of their top holdings — about 56% by weight.
JDOC is cheaper at 0.65% vs 0.75% — a difference of $10 a year per $10,000 invested.
Over one year, HRTS returned +23.6% vs +14.9% for JDOC.
Updated Nov 19, 2026
JDOC vs HRTS side by side
| JDOC | HRTS | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | J.P. Morgan | Innovator |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.65% | 0.75% |
| Annual cost per $10k | $65 | $75 |
| 10-yr cost on $10k (prospectus) | $810 | $1,168 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +14.9% | +23.6% |
| 5-yr return (annualized) | — | — |
| 10-yr return (annualized) | — | — |
| Best quarter | +11.3% | +15.8% |
| Worst quarter | −11.9% | −12.4% |
| Net assets (fund) | $9.1M | $51.9M |
| Number of holdings | 61 | 45 |
| Portfolio turnover | 92% | 4% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | JDOC | HRTS | Difference |
|---|---|---|---|
| 2025 | +14.9% | +23.6% | −8.7% |
| 2024 | −0.6% | +3.6% | −4.2% |
Source: Fund prospectus bar charts
Holdings overlap
14 of JDOC's top 25 holdings also appear in HRTS's top 25.
| Holding | JDOC | HRTS |
|---|---|---|
| AbbVie, Inc. | 7.85% | 2.40% |
| Eli Lilly & Co. | 7.76% | 11.52% |
| UnitedHealth Group, Inc. | 5.85% | 5.24% |
| Merck & Co., Inc. | 4.82% | 4.27% |
| Johnson & Johnson | 4.82% | 3.59% |
| AstraZeneca plc | 3.76% | 4.00% |
| Thermo Fisher Scientific, Inc. | 3.73% | 3.97% |
| Bristol-Myers Squibb Co. | 3.57% | 2.09% |
| Abbott Laboratories | 3.11% | 2.61% |
| Novo Nordisk A/S | 2.61% | 5.24% |
| Danaher Corp. | 2.16% | 2.66% |
| Edwards Lifesciences Corp. | 1.73% | 1.75% |
| Regeneron Pharmaceuticals, Inc. | 1.60% | 1.67% |
| Novartis AG | 1.60% | 3.38% |
Source: SEC Form N-PORT
JDOC top 10
- AbbVie, Inc. — 7.85%
- Eli Lilly & Co. — 7.76%
- UnitedHealth Group, Inc. — 5.85%
- Merck & Co., Inc. — 4.82%
- Johnson & Johnson — 4.82%
- AstraZeneca plc — 3.76%
- Thermo Fisher Scientific, Inc. — 3.73%
- Bristol-Myers Squibb Co. — 3.57%
- Abbott Laboratories — 3.11%
- CVS Health Corp. — 2.83%
HRTS top 10
- Eli Lilly & Co — 11.52%
- UnitedHealth Group Inc — 5.24%
- Novo Nordisk A/S — 5.24%
- Roche Holding AG — 4.50%
- Merck & Co Inc — 4.27%
- AstraZeneca PLC — 4.00%
- Thermo Fisher Scientific Inc — 3.97%
- Johnson & Johnson — 3.59%
- Gilead Sciences Inc — 3.43%
- Novartis AG — 3.38%
FAQ
What is the difference between JDOC and HRTS?
Which is cheaper, JDOC or HRTS?
Should I own both JDOC and HRTS?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.